Back to Drug Reference
Drug Reference

Anticoagulants

DOACs, warfarin, renal dosing, periprocedural management, reversal agents, and landmark trial evidence for cardiology practice.

Anticoagulation DOACs Warfarin Periprocedural
Updated: March 2026
1

DOAC Overview & Comparison

Direct oral anticoagulants (DOACs) have largely replaced warfarin for stroke prevention in non-valvular atrial fibrillation and for treatment of venous thromboembolism (VTE). They are classified by their target within the coagulation cascade: factor Xa inhibitors (apixaban, rivaroxaban, edoxaban) and the direct thrombin (factor IIa) inhibitor dabigatran.

Factor Xa inhibitors bind directly to the active site of factor Xa, blocking the conversion of prothrombin to thrombin. They inhibit both free and clot-bound factor Xa, as well as prothrombinase complex activity. Dabigatran is a competitive, reversible direct thrombin inhibitor that binds to the active site of both free and fibrin-bound thrombin, preventing fibrinogen cleavage to fibrin.

Landmark AF Trials

Each DOAC was validated in a pivotal phase III trial against dose-adjusted warfarin for stroke prevention in atrial fibrillation:

  • RE-LY (dabigatran) — Dabigatran 150 mg BID was superior to warfarin for stroke/systemic embolism with similar major bleeding; 110 mg BID was non-inferior with lower bleeding.
  • ROCKET-AF (rivaroxaban) — Rivaroxaban 20 mg daily was non-inferior to warfarin for stroke/systemic embolism, with similar major bleeding but less intracranial hemorrhage.
  • ARISTOTLE (apixaban) — Apixaban 5 mg BID was superior to warfarin for stroke/systemic embolism, caused less major bleeding, and demonstrated lower all-cause mortality.
  • ENGAGE AF-TIMI 48 (edoxaban) — Edoxaban 60 mg daily was non-inferior to warfarin for stroke/systemic embolism with significantly less major bleeding and cardiovascular mortality.
KEY DISTINCTIONS AMONG DOACs
  • Apixaban is the only DOAC with demonstrated superiority for both efficacy (stroke prevention) and safety (major bleeding) vs. warfarin in its pivotal AF trial.
  • Dabigatran is the only DOAC with a specific, FDA-approved reversal agent (idarucizumab) that provides complete reversal within minutes.
  • Rivaroxaban is the only DOAC dosed once daily for AF (with the evening meal to enhance absorption).
  • Edoxaban should not be used if CrCl >95 mL/min (increased stroke risk observed in ENGAGE AF).

DOAC Comparison Table

Parameter Apixaban Rivaroxaban Edoxaban Dabigatran
Mechanism Factor Xa inhibitor Factor Xa inhibitor Factor Xa inhibitor Direct thrombin inhibitor
AF dose (standard) 5 mg BID 20 mg daily (with food) 60 mg daily 150 mg BID
AF dose (reduced) 2.5 mg BID 15 mg daily 30 mg daily 75 mg BID
VTE treatment dose 10 mg BID x 7 days, then 5 mg BID 15 mg BID x 21 days, then 20 mg daily 60 mg daily (after 5-10 days of parenteral anticoagulation) 150 mg BID (after 5-10 days of parenteral anticoagulation)
Half-life ~12 hours 5-9 hours (young), 11-13 hours (elderly) 10-14 hours 12-17 hours
Renal clearance 27% 33% 50% 80%
Tmax 3-4 hours 2-4 hours 1-2 hours 1-2 hours
Prodrug No No No Yes (dabigatran etexilate)
Specific antidote Andexanet alfa Andexanet alfa Andexanet alfa (off-label) Idarucizumab
Landmark AF trial ARISTOTLE ROCKET-AF ENGAGE AF-TIMI 48 RE-LY
2

DOAC Renal Dosing Tables

Renal function is the single most important variable in DOAC dosing. Because dabigatran is 80% renally cleared, dose adjustments are particularly critical. Creatinine clearance (CrCl) should be estimated using the Cockcroft-Gault equation (not eGFR from CKD-EPI), as this was the method used in all pivotal trials. Renal function should be reassessed at least annually, and more frequently in patients with CKD stage 3 or higher.

Apixaban (Eliquis)

Apixaban dose reduction for AF requires meeting at least 2 of 3 criteria: age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL. Unlike other DOACs, apixaban dose reduction is not based solely on CrCl.

Indication CrCl / Criteria Dose
AF (standard) <2 of 3 dose-reduction criteria 5 mg BID
AF (reduced) ≥2 of 3: age ≥80, weight ≤60 kg, Cr ≥1.5 2.5 mg BID
AF + dialysis ESRD on hemodialysis 5 mg BID (or 2.5 mg BID if ≥2 criteria met)
VTE treatment CrCl >25 mL/min 10 mg BID x 7 days, then 5 mg BID
VTE extended prophylaxis CrCl >25 mL/min 2.5 mg BID
Pearl: The most common DOAC dosing error in clinical practice is inappropriate dose reduction of apixaban. Studies show that 10-15% of patients prescribed apixaban 2.5 mg BID do not meet dose-reduction criteria and are being underdosed. The ARISTOPHANES and other real-world analyses demonstrate that inappropriate dose reduction is associated with increased stroke risk without a significant reduction in bleeding. Always verify that at least 2 of the 3 criteria (age ≥80, weight ≤60 kg, Cr ≥1.5) are met before prescribing the reduced dose.

Rivaroxaban (Xarelto)

Indication CrCl Dose
AF >50 mL/min 20 mg daily with evening meal
AF (renal dosing) 15-50 mL/min 15 mg daily with evening meal
AF <15 mL/min or dialysis Avoid (limited data)
VTE treatment >30 mL/min 15 mg BID x 21 days, then 20 mg daily
VTE treatment (renal) <30 mL/min Avoid (limited data)

Edoxaban (Savaysa)

Indication CrCl / Criteria Dose
AF 51-95 mL/min 60 mg daily
AF (reduced) 15-50 mL/min, OR weight ≤60 kg, OR concurrent P-gp inhibitor 30 mg daily
AF >95 mL/min Do NOT use (increased stroke risk in ENGAGE AF)
AF <15 mL/min Avoid
VTE treatment >50 mL/min 60 mg daily (after 5-10 days parenteral anticoag)
VTE treatment (reduced) 15-50 mL/min, or weight ≤60 kg 30 mg daily

Dabigatran (Pradaxa)

Indication CrCl Dose
AF >30 mL/min 150 mg BID
AF (renal dosing) 15-30 mL/min 75 mg BID
AF <15 mL/min or dialysis Avoid (not studied, 80% renal clearance)
AF + concurrent P-gp inhibitor 30-50 mL/min 75 mg BID (avoid if CrCl <30 with P-gp inhibitor)
VTE treatment >30 mL/min 150 mg BID (after 5-10 days parenteral anticoag)
VTE treatment <30 mL/min Avoid
DIALYSIS CONSIDERATIONS
  • Apixaban is the only DOAC with FDA labeling supporting use in ESRD/dialysis (5 mg or 2.5 mg BID based on dose-reduction criteria). It has the lowest renal clearance (27%).
  • Dabigatran is approximately 60% dialyzable due to low protein binding (35%), but this is not a practical reversal strategy — idarucizumab is preferred.
  • Rivaroxaban and edoxaban are not recommended in ESRD/dialysis patients due to insufficient data.
  • For all DOACs in CKD, reassess CrCl at least every 3-6 months and after any acute illness or hemodynamic change.
3

Warfarin Management

Warfarin remains the anticoagulant of choice for mechanical heart valves, moderate-to-severe mitral stenosis, and patients with contraindications to DOACs. It exerts its anticoagulant effect by inhibiting vitamin K epoxide reductase (VKORC1), preventing the gamma-carboxylation of vitamin K-dependent clotting factors (II, VII, IX, X) and anticoagulant proteins C and S.

INR Targets

Indication Target INR Notes
Atrial fibrillation 2.0-3.0 Standard target for stroke prevention
VTE treatment/prophylaxis 2.0-3.0 Minimum 3 months for provoked VTE
Mechanical aortic valve (bileaflet, no risk factors) 2.0-3.0 On-X valve: INR 1.5-2.0 after 3 months (PROACT trial)
Mechanical mitral valve 2.5-3.5 Higher target due to increased thrombotic risk
Mechanical aortic valve + risk factors 2.5-3.5 Risk factors: AF, prior thromboembolism, LV dysfunction, older-generation valve
Antiphospholipid syndrome (thrombotic) 2.0-3.0 Some experts advocate 2.5-3.5 for arterial events

Initiation & Loading

For non-urgent initiation, start warfarin at 5 mg daily for most patients. Consider a lower starting dose of 2-3 mg daily in elderly patients (≥75 years), those with hepatic impairment, malnutrition, heart failure, or concomitant interacting medications. Avoid loading doses of 10 mg, which increase the risk of supratherapeutic INR and skin necrosis (due to early depletion of protein C before therapeutic anticoagulation is achieved). Check INR after 3-4 doses and adjust in 10-15% increments.

Drug Interactions

HIGH-YIELD WARFARIN DRUG INTERACTIONS
  • Amiodarone — Inhibits CYP2C9, CYP3A4, and CYP1A2; increases INR by approximately 50%. Reduce warfarin dose by 30-50% when initiating amiodarone and monitor INR weekly. The effect persists for weeks after amiodarone discontinuation due to its long half-life (~40-55 days).
  • Fluconazole / voriconazole — Potent CYP2C9 inhibitors; can double the INR. Reduce warfarin dose by 50% and monitor closely.
  • Rifampin — Potent CYP inducer; dramatically reduces warfarin effect. May require 2-3x the usual dose. Avoid combination if possible.
  • TMP-SMX (Bactrim) — Inhibits CYP2C9; can increase INR significantly within 3-5 days. One of the most common causes of warfarin-related bleeding events in clinical practice.
  • Metronidazole — Inhibits CYP2C9; increases INR. Reduce warfarin dose by 25-50%.
  • NSAIDs / aspirin — Increase bleeding risk through antiplatelet effects and GI mucosal injury; do not reliably change INR but markedly increase hemorrhagic complications.

Pharmacogenomics

Genetic variants in CYP2C9 (which metabolizes S-warfarin, the more potent enantiomer) and VKORC1 (warfarin's target enzyme) account for approximately 30-40% of inter-individual dose variability. The CYP2C9*2 and *3 alleles encode enzymes with reduced activity, requiring lower warfarin doses. The VKORC1 -1639G>A polymorphism (A allele) is associated with increased sensitivity to warfarin. While pharmacogenomic dosing algorithms exist (e.g., warfarindosing.org), the COAG and EU-PACT trials showed inconsistent benefit of genotype-guided dosing over clinical algorithms in diverse populations.

Warfarin Reversal

Scenario INR Management
Supratherapeutic, no bleeding 4.5-10.0 Hold warfarin; consider vitamin K 1-2.5 mg PO if high bleeding risk
Supratherapeutic, no bleeding >10.0 Hold warfarin + vitamin K 2.5-5 mg PO; recheck INR in 24 hours
Serious bleeding (any INR) Any 4-factor PCC (25-50 IU/kg) + vitamin K 10 mg IV; recheck INR in 15-30 min
Life-threatening bleeding / urgent surgery Any 4-factor PCC (dose per INR) + vitamin K 10 mg IV; FFP only if PCC unavailable

4-factor PCC (Kcentra) contains factors II, VII, IX, and X and reverses warfarin within 15-30 minutes. It is preferred over FFP due to faster onset, smaller volume (avoiding volume overload), no need for ABO matching, and more predictable factor repletion. Vitamin K should always be co-administered because PCC effect is transient (6-8 hours), while vitamin K takes 12-24 hours for full effect but provides sustained reversal.

Pearl: The SAMe-TT2R2 score predicts the likelihood of achieving good time in therapeutic range (TTR) on warfarin. Components: Sex (female, +1), Age <60 (+1), Medical history (at least 2 comorbidities, +1), Treatment interactions (+1), Tobacco use (+2), Race (non-Caucasian, +2). A score of 0-2 predicts good TTR; a score >2 suggests the patient may achieve poor TTR and would benefit from a DOAC instead.
4

Periprocedural Anticoagulation

Periprocedural anticoagulation management requires balancing thrombotic risk (stroke, valve thrombosis, recurrent VTE) against procedural bleeding risk. Two landmark trials have fundamentally shaped modern practice: the PAUSE trial (standardized DOAC interruption without bridging) and the BRIDGE trial (demonstrating that bridging anticoagulation is unnecessary for most AF patients on warfarin).

PAUSE Trial Protocol — DOAC Interruption

The PAUSE trial (2019) established a simple, standardized approach to perioperative DOAC management based on procedure bleeding risk and renal function (for dabigatran). No bridging was used. The strategy achieved low rates of both major bleeding (1.35%) and arterial thromboembolism (0.16%).

Drug CrCl Low Bleeding Risk (skip 1 dose pre-op) High Bleeding Risk (skip 2 doses pre-op) Resume Post-Op
Apixaban / Rivaroxaban / Edoxaban ≥30 mL/min Last dose ≥24 hours before Last dose ≥48 hours before 24 hours (low risk); 48-72 hours (high risk)
<30 mL/min Last dose ≥36 hours before Last dose ≥72 hours before
Dabigatran ≥50 mL/min Last dose ≥24 hours before Last dose ≥48 hours before 24 hours (low risk); 48-72 hours (high risk)
30-50 mL/min Last dose ≥36 hours before Last dose ≥72 hours before
<30 mL/min Last dose ≥48 hours before Last dose ≥96 hours before

Bridging Anticoagulation — The BRIDGE Trial

The BRIDGE trial (2015) randomized AF patients on warfarin undergoing elective procedures to perioperative bridging with dalteparin vs. placebo. The no-bridging group had significantly less major bleeding (1.3% vs. 3.2%) with no increase in arterial thromboembolism (0.4% vs. 0.3%). This trial established that bridging is unnecessary for most AF patients, including those with a CHA2DS2-VASc score up to 6.

WHEN TO BRIDGE (AND WHEN NOT TO)
  • Bridge: Mechanical heart valve (especially mitral position), VTE within the past 3 months, high-risk thrombophilia (e.g., antiphospholipid syndrome with prior event)
  • Do NOT bridge: AF without mechanical valve (even with high CHA2DS2-VASc), VTE >3 months ago, bioprosthetic valve, patients on DOACs (use PAUSE protocol instead)
  • Bridging regimen: Enoxaparin 1 mg/kg SC BID (start when INR <2.0, last dose ≥24 hours before procedure) OR UFH IV (stop 4-6 hours before procedure)
Pearl: Patients on DOACs should never be bridged with heparin products. The PAUSE trial demonstrated that simple interruption based on the drug's half-life and renal function is safe and effective. Bridging a DOAC patient exposes them to a period of triple-pathway anticoagulation risk (residual DOAC + heparin + rebound) with no demonstrated benefit.

Post-Procedure Resumption

For low bleeding-risk procedures (e.g., cataract surgery, minor dental, simple endoscopy without biopsy, pacemaker/ICD implantation), resume anticoagulation at full dose within 24 hours. For high bleeding-risk procedures (e.g., major surgery, spinal/epidural, kidney biopsy, complex ablation), delay resumption for 48-72 hours and consider half-dose anticoagulation for the first 1-2 days if hemostasis is uncertain. For AF ablation, most centers resume DOACs on the evening of the procedure or the following morning, given the high periprocedural stroke risk associated with left atrial instrumentation.

5

Reversal Agents & Special Situations

Idarucizumab (Praxbind) — Dabigatran Reversal

Idarucizumab is a humanized monoclonal antibody fragment (Fab) that binds dabigatran with 350x greater affinity than thrombin. It provides complete reversal within minutes. The RE-VERSE AD trial demonstrated that idarucizumab 5 g IV (given as two 2.5 g boluses no more than 15 minutes apart) achieved complete reversal of the anticoagulant effect in 98% of patients within 4 hours. Median time to hemostasis in actively bleeding patients was 2.5 hours.

Andexanet Alfa (Andexxa) — Factor Xa Inhibitor Reversal

Andexanet alfa is a modified recombinant factor Xa decoy protein that sequesters factor Xa inhibitors. It is FDA-approved for reversal of apixaban and rivaroxaban in life-threatening or uncontrolled bleeding. Dosing depends on the specific DOAC and time since last dose:

DOAC Last Dose / Timing Andexanet Bolus Andexanet Infusion
Apixaban (≤5 mg) or rivaroxaban (≤10 mg), or >8 hours since any dose Low dose or >8 h 400 mg IV at 30 mg/min 4 mg/min x 120 min (480 mg)
Apixaban >5 mg, rivaroxaban >10 mg, or unknown dose, within 8 hours High dose and ≤8 h 800 mg IV at 30 mg/min 8 mg/min x 120 min (960 mg)
PRACTICAL REVERSAL ALGORITHM FOR ACTIVE BLEEDING
  • Step 1: Identify the anticoagulant — check medication list, time of last dose, and renal function.
  • Step 2: For dabigatran — administer idarucizumab 5 g IV. For apixaban or rivaroxaban — administer andexanet alfa (dose per table). If andexanet unavailable, give 4-factor PCC 50 IU/kg.
  • Step 3: Supportive measures — tranexamic acid 1 g IV, maintain Hgb >7 g/dL (consider >8 in ACS/hemodynamic instability), correct coagulopathy (platelets >50k, fibrinogen >150 mg/dL).
  • Step 4: Source control — endoscopy, interventional radiology, or surgical intervention as indicated.
  • Step 5: Plan anticoagulation resumption — reassess thrombotic risk; most patients should restart anticoagulation within 1-2 weeks if bleeding source is controlled. Intracranial hemorrhage requires individualized risk-benefit discussion.

4-Factor PCC as Alternative

When specific reversal agents are unavailable, 4-factor PCC (Kcentra) at a dose of 50 IU/kg (not weight-based per INR, as with warfarin) can be used as an alternative for factor Xa inhibitors. PCC provides a substrate excess of clotting factors that partially overcomes the anticoagulant effect. It does not reverse dabigatran effectively (use idarucizumab). Activated PCC (FEIBA) 50 IU/kg is another option if standard PCC is unavailable.

DOACs in Obesity

The ISTH guidance suggests that DOACs may be used with standard dosing in patients with BMI ≤40 kg/m2 or weight ≤120 kg. For patients exceeding these thresholds, data are limited:

  • Apixaban — The most reassuring data. The ARISTOTLE subgroup analysis and subsequent real-world studies (including the ARISTOPHANES study) show consistent efficacy and safety across weight categories, including >120 kg. Standard dosing (5 mg BID) is generally recommended.
  • Rivaroxaban — Limited pharmacokinetic data in extreme obesity. Some experts consider drug-specific anti-Xa levels to verify adequate exposure, though clinical utility of levels is debated.
  • Dabigatran — Sparse data above 120 kg. Consider anti-IIa levels or alternative agent.
  • Edoxaban — Requires dose reduction to 30 mg daily for weight ≤60 kg; limited data in morbid obesity.

DOACs in Extremes of Weight and CKD

Patients who are simultaneously at extremes of weight AND have advanced CKD present the most challenging dosing scenarios. The opposing effects — obesity potentially reducing drug exposure while CKD increases it — make standard dosing unpredictable. In these patients, consider drug-specific anti-Xa levels (for apixaban/rivaroxaban), the dilute thrombin time (for dabigatran), or transition to warfarin with INR monitoring.

Left Atrial Appendage Closure (Watchman/Amulet)

Percutaneous LAA occlusion devices offer an alternative to long-term anticoagulation for stroke prevention in AF patients with contraindications to anticoagulation (e.g., major GI bleeding, intracranial hemorrhage, recurrent falls). The PROTECT AF and PREVAIL trials demonstrated non-inferiority of the Watchman device compared with warfarin for stroke prevention, with the benefit of eliminating long-term anticoagulation exposure. Post-implant anticoagulation protocols typically involve 45 days of warfarin + aspirin or 3-6 months of DOAC, followed by dual antiplatelet therapy, then aspirin monotherapy after 12 months (with some variation by center and device).

6

Key References

  1. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation (ARISTOTLE). N Engl J Med. 2011;365(11):981-992. doi:10.1056/NEJMoa1107039
  2. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation (RE-LY). N Engl J Med. 2009;361(12):1139-1151. doi:10.1056/NEJMoa0905561
  3. Douketis JD, Spyropoulos AC, Duncan J, et al. Perioperative management of patients with atrial fibrillation receiving a direct oral anticoagulant (PAUSE). JAMA Intern Med. 2019;179(11):1469-1478. doi:10.1001/jamainternmed.2019.2431
  4. Douketis JD, Spyropoulos AC, Kaatz S, et al. Perioperative bridging anticoagulation in patients with atrial fibrillation (BRIDGE). N Engl J Med. 2015;373(9):823-833. doi:10.1056/NEJMoa1501035
  5. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation (ENGAGE AF-TIMI 48). N Engl J Med. 2013;369(22):2093-2104. doi:10.1056/NEJMoa1310907